The Challenges of Developing New Drugs

The chance of a new drug under development, even after it has successfully passed animal models experiments, to obtain FDA approval is 1 in 100. It is still only 1 in 10 for the same new drug after it successfully passes Phase I human clinical trials.

It is very costly, lengthy and risky to develop new drugs. The inherent risk/reward trade-off of developing improved versions of existing drugs is fundamentally superior to that of new drug development efforts. This is the strong economic rationale behind Modigene`s business strategy.